NCT06642038
Efficacy and Safety of Transbronchial Bronchoscopic Thermal Vapor Ablation (BTVA) in Heterogeneous Emphysema
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
The forced expiratory volume in one second (FEV1) is used to assess lung function
Timeframe: 6 months
The Saint George's Respiratory Questionnaire-C (SGRQ-C) questionnaire was used to evaluate the value of patients' quality of life.
Timeframe: 6 months
Secondary (9)
FEV1 is used to assess lung function
The SGRQ-C questionnaire was used to evaluate the value of patients' quality of life.
Forced expiratory volume in one second/Forced vital capcacity(FEV1/FVC) were used to assess lung function
FVC were used to assess lung function
ResidualVolume (RV) were used to assess lung function
Show 4 moreShow less
Total Lung Capacity(TLC) were used to assess lung function
6 minute walking distance (6MWD) was used to assess exercise tolerance
Symptom scoring using COPD Assessment Test (CAT), modified Medical Research Council (mMRC) scoring table
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Arms and interventions
Experimental Group
Procedures: Transbronchial Endoscopic Thermal Vapor Ablation